PET/CT imaging with choline led to treatment changes in 48% of patients with recurrent prostate cancer, according to a Swiss study. The researchers said fluorine-18 choline-PET/CT should be used to restage patients with prostate-specific antigen levels of less than 2 ng/mL and Gleason scores -- a measure of determining disease severity -- of 7 or higher.

Related Summaries